UK Medicines Information
US FDA considers license extension to include use of dapagliflozin for heart failure
Information type:
Media and commentaries
Source:
BioSpace
Specialities:
Cardiovascular system disorders
Summary
An application has been submitted for the approval of dapagliflozin to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with HF with reduced ejection fraction with and without type 2 diabetes.
UKMi comment
The application is based on data from the phase III DAPA-HF and DELIVER trials.
Related links: